The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2013Identification of RNAs in Carrier Protein and Exosomes Compared to RNA Found in the Whole Sample
Objective/Rationale:
Isolation of RNA biomarkers from biofluids is a new promising approach to monitor health and disease. RNAs exist in different fractions of cell-free biofluids. Some are... -
Research Grant, 2013Inhaled Levodopa as a Treatment for Intermittent Motor Fluctuations in Parkinson’s Disease
Promising Outcomes of Original Grant:
Intrapulmonary delivery of levodopa results in rapid, consistent and predictable augmentation of plasma levodopa levels in both healthy volunteers and subjects... -
Rapid Response Innovation Awards, 2013Neuroprotectin D1 (NPD1) as a Disease-modifying Therapy for Parkinson’s Disease
Objective/Rationale:
Progressive loss of dopaminergic neurons in Parkinson’s disease (PD) involves several pathogenic mechanisms. It may be assumed that drugs acting on more than one... -
Rapid Response Innovation Awards, 2013Alpha-synuclein Picobody: A Novel Blood-Brain Barrier Permeable Diagnostic Ligand for Parkinson's Disease
Objective/Rationale:
The presence of the blood-brain barrier (BBB) has been an insurmountable impediment to successful drug delivery to the central nervous system. To circumvent the BBB... -
Research Grant, 2013Utility of a Novel Nicotinic Receptor Agonist for Treating Levodopa-induced Dyskinesia
Objective/Rationale:
It has been suggested that a nicotinic acetylcholine receptor (nAChR) agonists may restore the deficits caused by the loss of nicotinic acetylcholine subunits found in Parkinson’s... -
Therapeutic Pipeline Program, 2013Developing Disease-Modifying Therapies to Treat Parkinsons’s Disease by Enhancing the Clearance of Alpha Synuclein
Objective/Rationale:
This proposal seeks to develop a novel therapy that can slow the progression of Parkinson’s disease (PD) by optimizing chemical compounds that can decrease levels of alpha...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.